Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico

20 Oct 2020

Abstract excerpt

Favipiravir was initially developed as an antiviral drug against influenza and is currently used in clinical trials against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (COVID-19). This agent is presumably involved in RNA chain termination during influenza virus replication, although the molecular interactions underlying its potential impact on the coronaviruses including SARS-CoV-2,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33092045
DOI: 10.3390/microorganisms8101610

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In SilicoPMID 33092045Read ↗

Structural basis of SARS-CoV-2 polymerase inhibition by FavipiravirSemantic proximity Read ↗

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?Semantic proximity Read ↗

Exploring new antiviral targets for influenza and COVID-19: Mapping promising hot spots in viral RNA polymerasesSemantic proximity Read ↗

An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challengesSemantic proximity Read ↗

Potential use of RNA-dependent RNA polymerase (RdRp) inhibitors against SARS-CoV2 infectionSemantic proximity Read ↗

Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting virusesSemantic proximity Read ↗

RdRp inhibitors and COVID-19: Is molnupiravir a good option?Semantic proximity Read ↗

Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design ChallengeSemantic proximity Read ↗

SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspectiveSemantic proximity Read ↗

Potential and action mechanism of favipiravir as an antiviral against Junin virusSemantic proximity Read ↗

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesisSemantic proximity Read ↗

Remdesivir overcomes the S861 roadblock in SARS-CoV-2 polymerase elongation complexSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.